Skip to content
Big Pharma has taken much of the heat for sky-high insulin prices, but scrutiny could soon shift to other companies grabbing a growing slice of spending
Tags: Chuck Grassley , CI , Cigna , corporate , Corporate/Industrial News , CVS , CVS Health , Diabetes , diabetes drugs , Eli Lilly , Elon Musk , general News , Health , Healthcare , Healthcare/Life Sciences , hormone products , industrial news , Larry Levitt , life sciences , LLY , Maria Cantwell , medical conditions , medications , Neeraj Sood , pharmaceuticals , political , political/general news , ron wyden , specialized drugs , Specialized Drugs/Medications , SYND , UNH , UnitedHealth Group , WSJ-Pro-WSJ.com
Post navigation